ArticleJournal of neuro-oncology2026
Tumor-associated macrophages promote ferroptosis resistance in glioblastoma by stimulating iron-loaded extracellular vesicle release.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bidirectional regulation between ferroptosis and tumor-associated macrophages: mechanisms, strategies, and therapeutic perspectives.Frontiers in oncology · 2026Review
- Remodeling the tumor immune microenvironment: mechanisms of crosstalk between regulated cell death macrophages.Frontiers in immunology · 2026Review
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
purposeGlioblastoma (GBM) cells have a higher iron requirement than normal cells and therefore upregulate iron uptake. However, elevated intracellular iron levels can render cancer cells susceptible to ferroptosis, a non-apoptotic, iron-dependent form of cell death. Tumor-associated macrophages (TAMs) are the most abundant non-tumor cell type in GBM and play a pivotal role in GBM iron homeostasis. Although the role of TAMs in regulating iron availability in the TME is well established, their role in regulating ferroptosis in the GBM cells remains unexplored.
methodsA transwell coculture system was used involving GL261 cells and bone marrow–derived macrophages (BMDMs) from C57BL/6J mice to study cancer cell- TAM interaction in GBM. In vitro analyses including immunoblot, cell death assay, lipid peroxidation assay and labile iron pool measurements were done to examine the iron and ferroptotic status of GL261 cells. Extracellular Vesicles (EVs) were isolated by ultracentrifugation. Pharmacological inhibition of EVs was done to confirm the mechanism of action of TAM-induced ferroptosis resistance.
resultsTAMs rendered GL261 cells more resistant to RSL3-induced ferroptotic stress. Mechanistically, TAMs reduced Gl261 cellular iron levels by increasing the release of H-ferritin–bound iron via CD63-positive EVs, with a male sex bias. TAM-secreted TNF-α played a key role in promoting this ferritin-bound iron release. Treatment with GW4869, a potent inhibitor of EV formation, in the presence of hepcidin resensitized TAM-cocultured GL261 cells to RSL3-induced ferroptosis.
conclusionsThese findings indicate that TAMs protect GBM cells from ferroptotic stress by inducing EV-mediated ferritin-bound iron release from the GBM cells through TNF-α signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.